Eco Animal Health Group PLC is celebrating a major step forward in its mission to protect poultry health across Europe. The company’s shares climbed 8% on Monday after the European Medicines Agency (EMA) issued a positive opinion recommending authorisation of its new vaccine, Ecovaxxin MS.
This development marks a significant milestone for the London-based animal health company, which focuses on developing innovative treatments to support livestock wellbeing. The vaccine targets Mycoplasma synoviae, a bacterial infection that can cause painful inflammation in birds’ joints, bones, and respiratory systems. Such infections not only impact animal welfare but can also affect poultry productivity and overall flock health.
Ecovaxxin MS has been shown to help reduce air-sac and foot-pad lesions in chickens starting at just four weeks of age, improving both bird comfort and farm performance. With the EMA’s Committee for Medicinal Products for Veterinary Use offering its positive assessment, formal EU approval is expected in early 2026 — paving the way for commercial rollout in the second half of the year.
Eco Animal Health also plans to expand its global footprint by submitting regulatory applications in other regions over the next 12 months. Beyond Ecovaxxin MS, the company continues to advance several products aimed at enhancing animal health and reducing disease risk through innovative, science-based solutions.
This progress underscores how veterinary biotechnology is playing a growing role in sustainable food production — safeguarding the health of animals that, in turn, support human nutrition and food security.
